Inhaltsverzeichnis
Auswahl der wissenschaftlichen Literatur zum Thema „Glycosaminoglycans Metabolism“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Glycosaminoglycans Metabolism" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Glycosaminoglycans Metabolism"
Viola, Manuela, Timothy E. L. Douglas, Laura Alaniz und Barbara Bartolini. „Glycosaminoglycans Metabolism“. Biochemistry Research International 2012 (2012): 1–2. http://dx.doi.org/10.1155/2012/245792.
Der volle Inhalt der QuelleMironov, S. P., A. M. Gerasimov, L. N. Furtseva, A. G. Tikhomirov, D. O. Vasiliev und R. V. Merkurieva. „Oxyprolinuria and Glycosaminoglycansuria in Achilles Tendon Ruptures“. N.N. Priorov Journal of Traumatology and Orthopedics 5, Nr. 2 (15.06.1998): 51–53. http://dx.doi.org/10.17816/vto104492.
Der volle Inhalt der QuelleKoźma, Ewa M., Kornelia Kuźnik-Trocha, Katarzyna Winsz-Szczotka, Grzegorz Wisowski, Paweł Olczyk, Katarzyna Komosińska-Vassev, Mariusz Kasperczyk und Krystyna Olczyk. „Significant Remodeling Affects the Circulating Glycosaminoglycan Profile in Adult Patients with both Severe and Mild Forms of Acute Pancreatitis“. Journal of Clinical Medicine 9, Nr. 5 (01.05.2020): 1308. http://dx.doi.org/10.3390/jcm9051308.
Der volle Inhalt der QuelleWolf, Hanna, Andrea Graßmann, Romina Bester, André Hossinger, Christoph Möhl, Lydia Paulsen, Martin H. Groschup, Hermann Schätzl und Ina Vorberg. „Modulation of Glycosaminoglycans Affects PrPScMetabolism but Does Not Block PrPScUptake“. Journal of Virology 89, Nr. 19 (22.07.2015): 9853–64. http://dx.doi.org/10.1128/jvi.01276-15.
Der volle Inhalt der QuelleKittlick, P. D. „Inflammation, glycolytic metabolism, and glycosaminoglycans“. Experimental pathology 30, Nr. 1 (Januar 1986): 1–19. http://dx.doi.org/10.1016/s0232-1513(86)80051-2.
Der volle Inhalt der QuelleBower, L., C. Warren und G. Manley. „Human Serum and Urine Glycosaminoglycans in Health and in Patients with Chronic Renal Failure“. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 29, Nr. 2 (März 1992): 190–95. http://dx.doi.org/10.1177/000456329202900212.
Der volle Inhalt der QuelleKahaly, G., C. Stover, J. Beyer und E. Otto. „In vitro synthesis of glycosaminoglycans in endocrine ophthalmopathy“. Acta Endocrinologica 127, Nr. 5 (November 1992): 397–402. http://dx.doi.org/10.1530/acta.0.1270397.
Der volle Inhalt der QuelleChang, Chih-Cheng, Tien-Chun Chang, Shine CS Kao, Yea-Fhey Kuo und Li-Fei Chien. „Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial myxoedema“. Acta Endocrinologica 129, Nr. 4 (Oktober 1993): 322–27. http://dx.doi.org/10.1530/acta.0.1290322.
Der volle Inhalt der QuelleBondar', I. A., und V. V. Klimontov. „Glycosaminoglycans and diabetic nephropathy“. Problems of Endocrinology 50, Nr. 2 (15.04.2004): 29–34. http://dx.doi.org/10.14341/probl11392.
Der volle Inhalt der QuelleKAHALY, G., M. SCHULER, A. C. SEWELL, G. BERNHARD, J. BEYER und U. KRAUSE. „URINARY GLYCOSAMINOGLYCANS IN Graves'OPHTHALMOPATHY“. Clinical Endocrinology 33, Nr. 1 (Juli 1990): 35–44. http://dx.doi.org/10.1111/j.1365-2265.1990.tb00463.x.
Der volle Inhalt der QuelleDissertationen zum Thema "Glycosaminoglycans Metabolism"
Lewis, Martin David. „Human lysosomal sulphate transport“. Title page, contents and abstract only, 2001. http://web4.library.adelaide.edu.au/theses/09PH/09phl6752.pdf.
Der volle Inhalt der QuelleFreeman, Craig. „The lysosomal degradation of heparan sulphate : a comparative study of the physical and catalytic properties of the heparan sulphate degradative enzymes /“. Title page, contents and abstract only, 1991. http://web4.library.adelaide.edu.au/theses/09PH/09phf855.pdf.
Der volle Inhalt der QuelleNigro, Julie. „The role of PPAR-α ligands (fibrates) in the regulation of vascular smooth muscle proteoglycan synthesis and structure as a contributor to reduced lipoprotein binding and the development of atherosclerosis“. Monash University, Dept. of Medicine, 2004. http://arrow.monash.edu.au/hdl/1959.1/5464.
Der volle Inhalt der QuelleLeroux, Mélanie. „Production de glycosaminoglycanes par voie microbiologique et enzymatique“. Thesis, Université Grenoble Alpes (ComUE), 2019. http://www.theses.fr/2019GREAV024.
Der volle Inhalt der QuelleGlycosaminoglycans (GAGs) are long linear polysaccharide chains, found in all animals. Some pathogenic bacteria also synthesize polysaccharides identical or similar to human GAGs. This thesis deals with chondroitin sulfate and heparosan syntheses, members of the GAGs family. There is a growing interest in these two GAGs in the pharmaceutical industry due to numerous potential applications they offer. Chondroitin sulfate is currently extracted from animal tissues which can lead to sanitary problems such as viral or prion contaminations. On the other hand, a production process still needs to be developed for heparosan. Therefore, it is necessary to develop new methods for the production of these two polymers. Enzymatic synthesis, which is a promising alternative for the production of chondroitin sulfate and heparosan, was the subject of this thesis
Lucon, Marcos. „Avaliação do metabolismo de glicosaminoglicanos em pacientes portadores de cistite intersticial“. Universidade de São Paulo, 2012. http://www.teses.usp.br/teses/disponiveis/5/5153/tde-06022013-164806/.
Der volle Inhalt der QuelleIntroduction: interstitial cystitis is a chronic disease of the lower urinary tract whose symptoms are: increased urinary frequency, nocturia, perineal or pelvic pain that worses with bladder filling and improves with urination. The pathogenesis is not fully known, but there is evidence that proteoglycans and glycosaminoglycans lining the bladder urothelium can participate in its genesis. The loss of these protective compounds facilitate the contact of ions and solutes in the urine with deeper portions of bladder wall triggering and perpetuating a local inflammatory process. We investigated GAG behavior in urine and tissue (biopsy of bladder urothelium) of patients with IC/PBS and genuine stress urinary incontinence (SUI) in an attempt to better understand its metabolism. Patients and Methods: gene expression and glycosaminoglycans profile in tissue, and glycosaminoglycans profile in urine of 11 patients with interstitial cystitis were compared to 11 patients with pure urinary stress incontinence. Statistical analysis were performed using t Student test and Anova, considering significant when p<0,05. Results: patients with interstitial cystitis excreted lower concentration of glycosaminoglycans in urine when compared to those with pure urinary stress incontinence (respectively 0.45 + 0.11 x 0.62 + 0.13 mg/mg creatinine, p< 0.05). However, there was no reduction of the content of glycosaminoglycans in the urothelium of both patients. The immunofluorescence study showed that patients with interstitial cystitis had a stronger staining of TGF-beta, decorin (a proteoglycan of chondroitin/dermatan sulfate), fibronectin and hyaluronic acid. We were able to indentify by real-time PCR lower gene expression of hyaluronic acid synthases and hyaluronidase in the urothelium of patients with interstitial cystitis. Conclusion: the results suggest that glycosaminoglycans may be related to the ongoing process of inflammation and remodeling of the dysfunctional urothelium that is present in the interstitial cystitis. The study of the gene expression may represent an alternative to understand the disease
Robert, Joe͏̈lle. „Influence de divers constituants de la matrice extracellulaire sur le comportement de cellules dermiques d'embryon de poulet cultivées in vitro“. Grenoble 1, 1988. http://www.theses.fr/1988GRE10110.
Der volle Inhalt der QuelleDonida, Bruna. „Investigação dos biomarcadores de estresse oxidativo e inflamação em pacientes portadores de mucopolissacaridose tipo IVA submetidos à terapia de reposição enzimática“. reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2015. http://hdl.handle.net/10183/158766.
Der volle Inhalt der QuelleThe Mucopolysaccharidosis type IVA (MPS IVA) is a lysosomal storage disease caused by impaired degradation of keratan sulfate and chondroitin-6-sulfate glycosaminoglycans (GAG), due to a deficiency on the enzyme N-acetylgalactosamine-6-sulfatase. Since the pathophysiology of this disease is still not totally elucidated and many studies demonstrated the involvement of oxidative stress and inflammation in the pathogenesis of other mucopolysaccharidoses types, the principal objective of this study was to investigate oxidative stress parameters and inflammatory mediators in MPS IVA patients under enzyme replacement therapy (ERT). Urine anda blood samples of MPS IVA patients under ERT (n= 17) and healthy age-matched controls (n= 10-14) were evaluated. Patients presented a significant decrease in antioxidant defenses levels, assessed by reduced glutathione (GSH), and increased superoxide dismutase (SOD) activity in erythrocytes. With regard to the biomolecules damage, was observed that patients presented lipid peroxidation (increase of isoprostanes urinary levels) and protein damage (increase of di-tyrosine urinary levels and decrease of sulfhydryl groups in plasma), when compared to controls. Our results showed higher DNA damage levels in MPS IVA patients compared to control group, in both pyrimidines and purines bases. The pro-inflammatory cytokine interleukin 6 (IL-6) was significantly increased in patients and showed an inverse correlation with GSH levels, showing a possible link between inflammation and oxidative stress in MPS IVA disease. Considering that GAG urinary level were still high in ERT patients compared to the control group, we propose that GAG are, at least in part, related with oxidative damage found in MPS IVA patients. The data presented suggest that pro-inflammatory and pro-oxidant states occur in MPS IVA patients under ERT, and the supplementation of antioxidants in combination with ERT can be investigated with the purpose of improving the patient’s life quality. To the best of our knowledge, this is the first study in patients relating MPS IVA with oxidative stress and inflammation.
Franco, Renata Nogueron. „Biomarcadores do metabolismo da cartilagem e sua relação com as alterações morfológicas, inflamatórias e funcionais: um estudo sobre a lesão condral secundária em joelhos humanos“. Universidade Federal de São Carlos, 2011. https://repositorio.ufscar.br/handle/ufscar/5131.
Der volle Inhalt der QuelleOsteoarthritis (OA), a degenerative joint disease, is one of the most frequent causes of pain in the musculoskeletal system and of the inability to work in Brazil and the world. It is a multifactor, chronic disease, leading to progressive functional inability. It can arise as a result of injuries to structures such as the anterior crossed ligament and/or meniscus (post-traumatic OA), which, in this case, can affect individuals in any age range. The development of osteoarthritis includes multiple changes in the extracellular cartilage matrix, altering the normal morphological configuration of the joint involved, leading to a lack of equilibrium between the synthesis and degradation of products in this matrix. Although OA is not considered primordially as an inflammatory disease, inflammation of the joint has been shown to be a potential amplifier of the degenerative process. Thus the objective of the present study was to analyze potential biological markers in the serum and synovial fluid, and then correlate them with one another and with the morphological, inflammatory and functional alterations found in individuals with chronic injury of the anterior crossed ligament (ACL). The following techniques were used in the study: zymography, to determine the activity of the metallopeptidases 2 and 9 (MMP-2 and MMP-9); an immune-enzymatic assay (ELISA) to determine the presence of systemic and local cytokines; and a manual count of inflammatory cells (mononuclear and polymorphonuclear) by optical microscopy and spectrophotometry, in order to analyze for sulfated glycosaminoglycans (GAGs). The results indicated joint and systemic inflammation in chronic injury of the ACL by the detection of systemic and local cytokines, by the activity of MMP-9 and by the inflow of neutrophils. There were interactions between systemic and local cytokines, in which a cytokine did not always exert the same function in the serum as in the synovial fluid. The interleucines (IL) connected to degradation of the cartilage in chronic injury of the ACL were IL-12, IL-6 and IL-8, and those connected to pain and loss of function were IL-6 and IL-9. In counterpart, MMP-2 showed a negative correlation with the damage to the cartilage. It was concluded that the molecules studied had potential as biomarkers, since alterations were suggestive of injury and degradation of the cartilage. In addition, after the traumatic event resulting in rupture of the ACL, the ambient remained chronically inflamed and this inflammation was crucial for the high index of posttraumatic OA.
A osteoartrite (OA), doença articular degenerativa, é uma das causas mais freqüentes de dor do sistema músculo-esquelético e de incapacidade para o trabalho no Brasil e no mundo. É uma doença crônica, multifatorial, que leva a uma incapacidade funcional progressiva. Pode surgir em decorrência de lesões em estruturas como ligamento cruzado anterior e/ou meniscos (OA pós-traumática), e neste caso, pode afetar indivíduos em qualquer faixa etária. O desenvolvimento da osteoartrite inclui múltiplas mudanças na matriz extracelular da cartilagem, o que altera a configuração morfológica normal da articulação envolvida, levando a um desequilíbrio entre a síntese e degradação dos produtos desta matriz. Apesar da OA não ser considerada primordialmente como uma doença inflamatória, a inflamação articular tem demonstrado um potencial amplificador do processo degenerativo. Sendo assim, o objetivo deste trabalho foi analisar potenciais marcadores biológicos no soro e no líquido sinovial, e em seguida correlacioná-los uns com os outros e com as alterações morfológicas, inflamatórias e funcionais encontradas em sujeitos com lesão crônica do ligamento cruzado anterior (LCA). Para este estudo foram utilizadas técnicas de: zimografia, para verificar a atividade das metalopeptidases 2 e 9 (MMP-2 e MMP-9); Ensaio imunoenzimático (ELISA), para constatar a presença das citocinas sistêmicas e locais; contagem manual de células inflamatórias (mononucleares e polimorfonucleares) por microscopia óptica e espectrofotometria para a análise dos glicosaminoglicanos sulfatados (GAGs). Os resultados apontaram para uma inflamação articular e sistêmica na lesão crônica do LCA, pela detecção de citocinas sistêmicas e locais, pela atividade das MMP-9 e pelo influxo de neutrófilos. Houve interações entre citocinas sistêmicas e locais, nas quais nem sempre uma citocina exerce a mesma função no soro e no líquido sinovial. As interleucinas (IL) ligadas à degradação da cartilagem na lesão crônica do LCA foram IL-12, IL-6 e IL-8 e as ligadas à dor e a perda de função foram IL-6 e IL-8. Em contrapartida, a MMP-2 apresentou correlação negativa com os danos na cartilagem. Conclui-se que, as moléculas estudadas apresentam potencial como biomarcadores, sendo suas alterações sugestivas de lesão e degradação da cartilagem. E ainda, que após o evento traumático responsável pelo rompimento do LCA, o ambiente permanece inflamado cronicamente e que esta inflamação é crucial para o alto índice de OA pós-traumática.
Lewis, Martin D. „Human lysosomal sulphate transport / Martin David Lewis“. 2001. http://hdl.handle.net/2440/21672.
Der volle Inhalt der QuelleIncludes bibliographical references (leaves 266-287).
xxiv, 289 leaves, [2] leaves of plates : ill. ; 30 cm.
Title page, contents and abstract only. The complete thesis in print form is available from the University Library.
Thesis (Ph.D.)--University of Adelaide, Dept. of Paediatrics, 2001
Freeman, Craig. „The lysosomal degradation of heparan sulphate : a comparative study of the physical and catalytic properties of the heparan sulphate degradative enzymes / by Craig Freeman“. Thesis, 1991. http://hdl.handle.net/2440/19747.
Der volle Inhalt der QuelleIncludes bibliographic references
2 v. (various foliations) : ill ; 30 cm.
Summary: Studies the enzymology of some of the nine lysosomal exo-enzyme activities which act together to degrade the more highly sulphated regions of the glycosaminoglycans heparin and heparan sulphate. A deficiency of any one of these enzyme activities can result in one of the lysosomal storage disorders collectively known as the Mucopolysaccharidoses (MPS)
Thesis (Ph.D.)--University of Adelaide, Dept. of Paediatrics, 1991
Bücher zum Thema "Glycosaminoglycans Metabolism"
The role of proteoglycans and glycosaminolglycans in aging. Basel: Karger, 1994.
Den vollen Inhalt der Quelle finden(Editor), Vittorio Zambotti, Hrsg. Glycolipids, Glycoproteins, and Mucopolysaccharides of the Nervous System. Springer, 1995.
Den vollen Inhalt der Quelle findenFrawley, Geoff. Mucopolysaccharidoses. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199764495.003.0064.
Der volle Inhalt der QuelleBuchteile zum Thema "Glycosaminoglycans Metabolism"
Linhardt, R. J., D. Loganathan, A. Al-Hakim und S. A. Ampofo. „Structure and Metabolism of Glycosaminoglycans“. In New Trends in Haemostasis, 12–26. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-84318-1_2.
Der volle Inhalt der QuelleKreysel, H. W., und H. P. Nissen. „Glycosaminoglycan Metabolism“. In Hair and Hair Diseases, 255–65. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74612-3_11.
Der volle Inhalt der QuelleJones, Simon, und Frits A. Wijburg. „Glycosaminoglycans and Oligosaccharides Disorders: Glycosaminoglycans Synthesis Defects, Mucopolysaccharidoses, Oligosaccharidoses and Sialic Acid Disorders“. In Inborn Metabolic Diseases, 765–83. Berlin, Heidelberg: Springer Berlin Heidelberg, 2022. http://dx.doi.org/10.1007/978-3-662-63123-2_41.
Der volle Inhalt der QuelleFluharty, Arvan L. „Diseases of Glycosaminoglycan and Proteoglycan Metabolism“. In Connective Tissue Disease, 491–521. Boca Raton: CRC Press, 2021. http://dx.doi.org/10.1201/9781003210016-25.
Der volle Inhalt der QuelleKopper, László, József Timár, András Jeney und Károly Lapis. „Glycosaminoglycan (GAG) Metabolism as a Potential Target to Prevent Metastasis Formation“. In Advances in Experimental Medicine and Biology, 367–75. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4899-5037-6_40.
Der volle Inhalt der QuelleHARDINGHAM, TIM. „Proteoglycans and Glycosaminoglycans“. In Dynamics of Bone and Cartilage Metabolism, 85–98. Elsevier, 2006. http://dx.doi.org/10.1016/b978-012088562-6/50006-6.
Der volle Inhalt der QuelleHARDINGHAM, T. „Proteoglycans and Glycosaminoglycans“. In Dynamics of Bone and Cartilage Metabolism, 85–98. Elsevier, 2006. http://dx.doi.org/10.1016/b9-78-012088-5/62650-0066.
Der volle Inhalt der QuelleLachmann, Robin H. „Disorders of Carbohydrate Metabolism“. In Oxford Textbook of Endocrinology and Diabetes 3e, herausgegeben von John A. H. Wass, Wiebke Arlt und Robert K. Semple, 1893–901. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198870197.003.0234.
Der volle Inhalt der QuelleCervós-Navarro, Jorge, und Henry Urich. „Disorders of Glycosaminoglycan Metabolism (Mucopolysaccharidoses)“. In Metabolic and Degenerative Diseases of the Central Nervous System, 110–36. Elsevier, 1995. http://dx.doi.org/10.1016/b978-012165250-0/50004-0.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Glycosaminoglycans Metabolism"
Vannucchi, S., F. Pasquali, P. Bianchi-ni und M. Ruggiero. „BINDING AND METABOLISM OF HEPARIN BY ENDOTHELIAL CELLS“. In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644187.
Der volle Inhalt der QuelleSmith, Robert Lane. „Mechanical Loading and Articular Cartilage Metabolism“. In ASME 2000 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2000. http://dx.doi.org/10.1115/imece2000-2520.
Der volle Inhalt der Quelle